Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website http://www.thejh.org

Case Report

Volume 6, Number 4, October 2017, pages 96-100

A Case of Therapy-Related Acute Myeloid Leukemia in a Patient With Heterozygous Mutations in the Ataxia Telangiectasia Mutated Gene

Figures

Figure 1.
Figure 1. Hypercellular bone marrow with myeloblasts (× 20 magnification).
Figure 2.
Figure 2. Myeloblasts with high nucleus to cytoplasm ratio (×100 magnification).

Table

Table 1. Therapy-Related AML Caused by Previous Chemotherapy
 
Topoisomerase II inhibitors (e.g. doxorubicin)Alkylating agents (e.g. cyclophosphamide)
Onset of t-AML2 - 3 years after exposure4 - 7 years after exposure
Pre-leukemic phaseNo preceding myelodysplastic phase; frequently presents as overt acute leukemia often with monocytic componentPatients may present with MDS or AML with myelodysplastic features
Cytogenetic abnormalities previously documentedTranslocations to 11q23
Translocations to 11p15
Translocations to 21q22
Translocations to 16q22
inv(16)(p13q22)
t(15;17)(q22;q12)
t(11;16)(q23;p13.3)
t(8;21)
t(9;11)		Deletions or monosomy of chromosome 5 or 7
t(3;21)
PrognosisSimilar to cases of de novo AML with corresponding genetic abnormalitiesWorse than de novo AML